Evidence supporting the use of: Ostarine
For the health condition: Osteoporosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Ostarine (also known as MK-2866 or Enobosarm) is a selective androgen receptor modulator (SARM) developed to treat conditions involving muscle and bone wasting, such as osteoporosis. Preclinical studies in animal models have shown that Ostarine can increase bone mineral density and improve bone strength, likely by stimulating androgen receptors in bone tissue without many of the side effects associated with traditional anabolic steroids. Several early-phase human clinical trials have assessed its effects on muscle mass and function, but data specific to osteoporosis and bone outcomes in humans are limited.

One phase II clinical trial (Dalton et al., 2011, Journal of Cachexia, Sarcopenia and Muscle) demonstrated that Ostarine increased lean body mass in elderly men and postmenopausal women, a population at risk for osteoporosis. However, direct evidence for fracture reduction or significant increases in bone mineral density in osteoporotic patients is lacking. The theoretical rationale for Ostarine’s use in osteoporosis is supported by its anabolic effects on bone in animal studies and its ability to increase muscle mass, which may indirectly reduce fracture risk by improving mobility and reducing falls.

Overall, while there is scientific rationale and some preliminary evidence supporting the use of Ostarine for osteoporosis, robust clinical trial data in humans demonstrating clear benefits for bone health are currently insufficient. The evidence base is limited, and Ostarine is not approved by regulatory agencies for the treatment of osteoporosis.

More about Ostarine
More about Osteoporosis

Products containing Ostarine

We currently have no products on Vitabase that contain this ingredient.